New combo therapy aims to shrink hard-to-treat liver tumors
NCT ID NCT03457948
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This study tests whether adding an immunotherapy drug (pembrolizumab) to either liver-directed treatments or a type of radiation therapy (PRRT) can shrink tumors in people with advanced neuroendocrine tumors that have spread to the liver. About 32 adults with well-differentiated tumors are taking part. The goal is to see if the combination works better than immunotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.